Introduction
============

The advancement in biotechnologies has revolutionized numerous disciplines including biology and medicine. Several high-throughput platforms including whole genome arrays and the next-generation sequencing instruments are available for profiling large-scale omics data. These cutting edge biotechnologies have spurred rapid biomarker discovery and personalized medicine approach in multiple diseases, in particular, cancer research. In recent years, genomewide profiling utilizing these technologies has been carried out to identify biomarkers associated with cancer development and progression. In this paper, we consider the matched pairs samples for identifying differentially expressed biomarkers between two groups. Matched/paired study design is commonly used in omics/biomarkers profiling because it automatically accounts for confounding factors. Examples of matched/paired designs include profiling *n* (1) tumor and adjacent normal lesions, (2) pre- and post-drug treatment samples, or (3) one-to-one matching of patients by demographic covariates (eg, age, gender, race, etc.) from the two groups of interest. We will use the tumor versus normal samples hereafter for expository purpose.

Ideally, one expects a total of 2*n* samples from such matched/paired design. However, in practice, circumstances such as RNA degradation, array failure, or insufficient resources could result in a subset of patients missing in either the tumor or matched normal biomarker profiles. For example, *n*~1~(\<*n*) patients have both the tumor and matched normal profiles, whereas *n*~2~ and *n*~3~ patients have only tumor and normal samples, respectively. Such incomplete or missing paired samples are also known as partially matched samples.

Several methods have been developed to analyze partially matched data generated from the Gaussian distribution.[@b1-cin-suppl.7-2014-001]--[@b4-cin-suppl.7-2014-001] Recently, Kuan and Huang[@b5-cin-suppl.7-2014-001] and Yu et al.[@b6-cin-suppl.7-2014-001] extended the approach to non-parametric setting, which does not require the Gaussian assumption. Specifically in Kuan and Huang,[@b5-cin-suppl.7-2014-001] we introduced a simple and robust method for analyzing partially matched samples based on the weighted *Z*-test to combine the *P*-values computed using (1) paired sample tests (eg, paired *t*-test or Wilcoxon sign rank test) on the *n*~1~ matched pairs and (2) two-sample tests (eg, two-sample *t*-test or Mann--Whitney test) on the incomplete *n*~2~ and *n*~3~ pairs. The *P*-value pooling approach has been shown to achieve good operating characteristics compared to existing methods.

As alluded earlier, matched/paired design is an appealing approach to avoid confounding. However, when a subset of samples has incomplete pairs in partially matched samples scenarios, this can result in unbalanced covariates between the tumor and normal groups. Nonetheless, the above-mentioned methods assume that the confounding factors among the *n*~2~ and *n*~3~ incomplete matched pairs are absent or negligible. If this assumption does not hold, the conclusions drawn from these methods are no longer valid. In this paper, we introduce an approach to adjust for potential confounders based on propensity score matching method in partially matched samples. Our paper is organized into five sections. In Section 2, we describe the proposed method, followed by Sections 3 and 4, which demonstrate the operating characteristics of the proposed approach in simulations and case study, respectively. We conclude with a discussion in Section 5.

Method
======

Let (*X*~i~, *Y*~i~) be a matched pair for subject *i*, *i* = 1, ..., *n*, where *X~i~* and *Y~i~* are the tumor and normal measurements, respectively. Without loss of generality, we assume that (*X~i~*, *Y~i~*) are complete matched pairs for *i* = 1, ..., *n*~1~; *Y~i~*'s are missing for *i* = *n*~1~ + 1, ..., *n*~1~ + *n*~2~, and *X~i~*'s are missing for *i* = *n*~1~ + *n*~2~ + 1, ..., *n*~1~ + *n*~2~ + *n*~3~. That is, *n*~1~ patients have both the tumor and matched normal profiles, whereas *n*~2~ and *n*~3~ patients have only tumor or normal samples, respectively. Let ***Z****~i~* = (*Z*~1~*~i~*, ..., *Z~pi~*) denote the *p* covariates for subject *i*, for instance, *Z*~1~*~i~* = age, *Z*~2~*~i~* = gender, etc. The first step is to create pseudo-pairs between the *n*~2~ and *n*~3~ incomplete pairs by matching the covariate information. We will use propensity score method to accomplish this step. To simplify the notation, we introduce subscript *j* to denote sample *j*, *j* = 1, ..., *n*~2~ + *n*~3~ among the incomplete pairs, and let ***Z****~j~* denote the corresponding covariate information. Let *O~j~* denote the measurement for subject *j*. Note that *O~j~* = *X~j~* for *j* = 1, ..., *n*~2~ and *O~j~* = *Y~j~* for *j* = *n*~2~ + 1, ..., *n*~2~ + *n*~3~. We also let *G~j~* denote the group indicator for sample *j*, ie, *G~j~* = 1 and 2 for normal and tumor samples, respectively.

Propensity score method
-----------------------

The propensity score method, introduced by Rosenbaum and Rubin,[@b7-cin-suppl.7-2014-001] is a popular approach in observational studies to create balance in multiple confounding covariates between the two groups. The propensity score is defined as $$\left. e_{j} = P(G_{j} = 2 \middle| Z_{j}) \right.$$

There are several approaches for estimating *e~j~*, including logistic regression and machine learning techniques such as boosted regression,[@b8-cin-suppl.7-2014-001] classification trees (CART), and random forests. A comparison of these methods is provided in Lee et al.[@b9-cin-suppl.7-2014-001]

There are four main methods for removing confounding effects based on *e~j~*, namely (1) propensity score matching, (2) stratification on propensity score, (3) covariate adjustment using propensity score, and (4) inverse probability weighting by propensity score. We refer the readers to Austin[@b10-cin-suppl.7-2014-001] for a review on these different approaches. In this paper, we consider two approaches based on propensity scores to account for confounding effects. The first approach is covariate adjustment using propensity score via a linear model $$O_{j} = \beta_{0} + \beta_{G}G_{j} + \beta_{e}e_{j} + \varepsilon_{j}$$

where *ε~j~* \~ *N*(0, 1) if the biomarker measurements are approximately Gaussian distributed after appropriate normalization and transformation. Otherwise, one can use the generalized linear model[@b11-cin-suppl.7-2014-001] with appropriate link function for non-Gaussian data. One can then evaluate if the expression of tumor is significantly different from normal by testing the hypothesis *H*~0~: *β~G~* = 0.

The second approach is based on Mahalanobis distance on covariate ranks with propensity score caliper[@b12-cin-suppl.7-2014-001] for matching the covariates between the *n*~2~ tumor and *n*~3~ normal samples from incomplete pairs. Let ***r****~j~* be the vectors of covariate ranks for sample *j*. The Mahalanobis distance between sample *j* in the tumor group and sample *k* in the normal group is defined as $$d_{jk} = (r_{j} - r_{k})\prime{\overset{\frown}{\sum}}^{- 1}(r_{j} - r_{k})$$

where $\overset{\frown}{\sum}$ is the estimated pooled covariance matrix for the ranks. On the other hand, the propensity score caliper *c* is defined as the maximum propensity score distance between sample *j* and *k* allowed within a match. In other words, $$d_{jk} = \begin{cases}
{(r_{j} - r_{k})\prime{\overset{\frown}{\sum}}^{- 1}(r_{j} - r_{k})} & {\text{if~}D(e_{j},e_{k}) \leq c} \\
\infty & \text{otherwise} \\
\end{cases}$$

The choice of caliper width is related to bias--variance trade-off where small caliper width results in bias reduction but at the expense of increasing variance, and vice versa.[@b13-cin-suppl.7-2014-001] A few studies have been conducted to investigate the optimal caliper width in propensity score matching, including the work of Austin[@b13-cin-suppl.7-2014-001] and Wang et al.[@b14-cin-suppl.7-2014-001] Based on these works and our own experience in propensity score matching, we recommend using caliper width equal to 0.2 of the standard deviation of the logit of the propensity score, which tends to have better performance, ie, $$D(e_{j},e_{k}) = \frac{\left| \log\ {it}(e_{j}) - \log\ {it}(e_{k}) \right|}{\sqrt{\left( {\gamma_{1}^{2} + \gamma_{2}^{2}} \right)}/2}\qquad\text{and}\qquad c = 0.2$$

where $\gamma_{G}^{2}$ is the variance of logit of the propensity score in the *G*th group. The samples are matched using the optimal full matching algorithm.[@b15-cin-suppl.7-2014-001]--[@b17-cin-suppl.7-2014-001] Matching algorithm aims to group tumor and normal samples that have similar covariates, ie, small *d~jk~*. Optimal full matching subdivides the samples into collection of matched sets ***S***, where each set consists of a tumor with any number of normal samples or a normal sample with any number of tumors by minimizing the net discrepancy Σ*~j~*~,~*~k∈S~d~jk~* [@b15-cin-suppl.7-2014-001],[@b17-cin-suppl.7-2014-001] The Olsen's algorithm is used to create optimal matching (see Hansen[@b15-cin-suppl.7-2014-001] and Hansen and Klopfer[@b16-cin-suppl.7-2014-001] for details).

Test statistics for matched set
-------------------------------

The tumor and normal samples within each matched set tend to be correlated since they have comparable baseline covariates.[@b7-cin-suppl.7-2014-001],[@b18-cin-suppl.7-2014-001] For one-to-one pairing, one usually uses paired sample *t*-test or Wilcoxon signed-rank test to test if the expression level of tumors is significantly different from the normal samples. However, in the full matching scenario, each tumor is paired with several normal samples and vice versa; thus, the paired sample *t*-test or Wilcoxon signed-rank test needs to be generalized to such one-to-many pairing. In this paper, we consider a generalization of the paired sample *t*-test under the scenario that the biomarker measurements are approximately Gaussian distributed. Following Rosner,[@b19-cin-suppl.7-2014-001] a generalized paired sample *t*-test can be derived based on a one-way random effects ANOVA model given by $$d_{s} = {\overline{X}}_{s} - {\overline{Y}}_{s} = \alpha + \delta_{s} + \varepsilon_{s},\quad s = 1,\ldots,S$$

where *α* is the overall within-pair mean difference between tumor and normal samples, $\left. \delta_{s} \right.\sim N(0,\sigma_{D}^{2})$ is the random effect for the *s*th pairing, $\left. \varepsilon_{s} \right.\sim N(0,\sigma_{s}^{2})$ is the random error, and *S* is the total number of matched sets. In addition, *σ~s~* = *σ*^2^ (1/*m*~1~*~s~* + 1/*m*~2~*~s~*) where *m*~1~*~s~* and *m*~2~*~s~* are the number of tumors and normals in matched set *s*, respectively. The hypothesis for testing if the expression of tumor is different from normal samples translates into testing *α* = 0. The test statistic is given by $$\hat{t} = \hat{\alpha}/{(V_{11})}^{1/2}$$

where $$V_{11} = \frac{\left\{ {{\sum_{s = 1}^{S}w_{s}^{3}}{(d_{s} - \hat{\alpha})}^{2} - {\sum_{s = 1}^{S}w_{s}^{2}}/2} \right\}}{\left\lbrack {\left( {\sum_{s = 1}^{S}w_{s}} \right)\left\{ {{\sum_{s = 1}^{S}w_{s}^{3}}{(d_{s} - \hat{\alpha})}^{2} - {\sum_{s = 1}^{S}w_{s}^{2}}/2} \right\} - \left\{ {{\sum_{s = 1}^{S}w_{s}^{2}}(d_{s} - \hat{\alpha})} \right\}^{2}} \right\rbrack}$$

and $$w_{s} = \frac{1}{{\hat{\sigma}}_{D}^{2} + {\hat{\sigma}}_{s}^{2}}$$

*σ*^2^ is estimated using the usual unbiased estimator, whereas α and $\sigma_{D}^{2}$ are estimated using numerical methods (see Rosner[@b19-cin-suppl.7-2014-001] for details). For large samples, the *P*-value of $\hat{t}$ can be obtained from the asymptotic distribution *N*(0, 1). For small samples, the *P*-value can be computed from the permutation test, by permuting the labels of tumor and normal samples within each matched set. Suppose there are *m*~1~*~s~* tumors and a total of *N~s~* samples in matched set *s*, then the total number of possible permutations is $\prod_{s = 1}^{S}\left( {}_{m_{1s}}^{N_{s}} \right)$.

On the other hand, the generalized non-parametric test for one-to-many pairing can be carried out via the aligned rank test of Hodges and Lehmann[@b20-cin-suppl.7-2014-001] if the data are non-Gaussian. We refer the readers to Hodges and Lehmann,[@b20-cin-suppl.7-2014-001] and Heller et al.[@b21-cin-suppl.7-2014-001] for additional details on implementing the aligned rank test.

*P*-values pooling
------------------

We follow the idea of our earlier work in Kuan and Huang[@b5-cin-suppl.7-2014-001] to test if the biomarker is significantly up or down regulated in tumor compared to normal samples by pooling the *P*-values from the *n*~1~ complete and (*n*~2~, *n*~3~) incomplete pairs. The *P*-value for the *n*~1~ complete matched pairs is computed using either the paired sample *t*-test or Wilcoxon signed-rank test, denoted as *p*~1~. On the other hand, the *P*-value for the incomplete pairs *p*~2~ is computed based on the linear model using propensity score as covariate ([equation (1)](#fd2-ehi-suppl.2-2014-009){ref-type="disp-formula"} of Section 2.1), the generalized *t*-test, or aligned signed rank test (Section 2.2). The next step is to pool the two *P*-values by borrowing the idea of meta-analysis. Several methods are available for pooling *P*-values including the inverse normal and Fisher's methods. In Kuan and Huang,[@b5-cin-suppl.7-2014-001] we showed that pooling *P*-values based on weighted *Z*-test has good operating characteristics compared to other methods. The weighted *Z*-test for combining the *P*-values is based on transforming the *P*-values into Z-score *Z~a~* = Φ^−1^(1 − *p~k~*), *k* = 1, 2. The combined *P*-value by the weighted *Z*-test[@b5-cin-suppl.7-2014-001],[@b22-cin-suppl.7-2014-001] is given by $$p_{c} = 1 - \Phi\left( \frac{w_{1}Z_{1} + w_{2}Z_{2}}{\sqrt{w_{1}^{2} + w_{2}^{2}}} \right)$$

where *w~k~*'s are the corresponding weights. Although different choices of weights have been proposed in the literature, Kuan and Huang,[@b5-cin-suppl.7-2014-001] Zaykin[@b23-cin-suppl.7-2014-001] showed that setting the weights as the square root of the sample sizes works well in practice. Thus, we set $w_{1} = \sqrt{2n_{1}}$ and $w_{2} = \sqrt{n_{2} + n_{3}}$. In addition, pooling *P*-values is only meaningful if *p*~1~ and *p*~2~ are computed from one-sided hypothesis tests to avoid directional conflict. One can obtain a two-sided combined *P*-value as follows. Let *p*~1~ and *p*~2~ be the one-sided *P*-value for the same alternative (eg, "greater") hypothesis, and *p*~c~ be the combined one-sided *P*-value from [equation (2)](#fd10-ehi-suppl.2-2014-009){ref-type="disp-formula"}. The two-sided *P*-value is given by $$p_{c}^{*} = \begin{cases}
{2p_{c}} & {\text{if~}p_{c} < 1/2} \\
{2(1 - p_{c})} & \text{otherwise} \\
\end{cases}$$

Simulation
==========

We carry out simulation to evaluate the performance of propensity score method to adjust for potential confounders in partially matched samples. *n* paired sample measurements (*X~ij~*, *Y~ij~*) of a biomarker *i* for the tumor and matched normal group are generated from bivariate Gaussian distribution, $$\left. \begin{pmatrix}
X_{ij} \\
Y_{ij} \\
\end{pmatrix} \right.\sim N\left( \begin{pmatrix}
{\mu_{X} + \beta Z_{1} - \beta\log(Z_{2})} \\
{\mu_{Y} + \beta Z_{1} - \beta\log(Z_{2})} \\
\end{pmatrix} \right),\begin{pmatrix}
\sigma_{X}^{2} & {\rho\sigma_{X}\sigma_{Y}} \\
{\rho\sigma_{X}\sigma_{Y}} & \sigma_{Y}^{2} \\
\end{pmatrix}$$

where *Z*~1~ and *Z*~2~ are confounders, and *μ~X~* and *μ~Y~* are the true mean expressions for tumor and normal groups, respectively. We consider (*n*~1~, *n*~2~, *n*~3~) = (70, 15, 15), (50, 25, 25), and (30, 35, 35) and set *σ~X~* = *σ~Y~* = 1, whereas *ρ* \~ *U*(0, 1) to capture various degrees of correlation between tumor and normal matched pairs. In addition, we set *μ~Y~* = 0 and *μ~X~* = 0, 0.1, 0.2, ..., 0.5 for different effect sizes, and *β* = 0, 0.5, 1, and 2 for zero, moderate, strong, and very strong confounding effects. To simulate unbalanced confounders arising from incomplete matched pairs, we generate *Z*~1~, *Z*~2~ \~ *N*(0, 1) for *i* = 1, ..., *n*~1~, *Z*~1~ \~ *N*(−0.2, 1), *Z*~2~ \~ *N*(0.2, 1) for *i* = *n*~1~ + 1, ..., *n*~1~ + *n*~2~, and *Z*~1~ \~ (0.2, 1), *Z*~2~ \~ *N*(−0.2, 1) for *i* = *n*~1~ + *n*~2~ + 1, ..., *n*~1~ + *n*~2~ + *n*~3~.

We compare the performance of the following methods in our simulation studies: Gold standard (Gold-std): The *P*-value was computed from paired sample *t*-test on *n*~1~ + *n*~2~ + *n*~3~ original matched pairs assuming complete data set. This is the reference test.Paired only: The *P*-value was computed from paired sample *t*-test on the *n*~1~ complete matched pairs only, and discarding the *n*~2~ and *n*~3~ incomplete pairs.Two sample: Combining the *P*-value from paired sample *t*-test on the complete *n*~1~ matched pairs and the *P*-value from two-sample *t*-test on the incomplete *n*~2~ and *n*~3~ samples using the weighted *Z*-test approach.[@b5-cin-suppl.7-2014-001]Propensity score with full matching (FM-PS): Combining the *P*-value from paired sample *t*-test on the complete *n*~1~ matched pairs and the *P*-value from generalized *t*-test on full matched data by Mahalanobis distance with propensity score caliper *c* = 0.2 on the incomplete *n*~2~ and *n*~3~ samples.Propensity score with regression adjustment (Reg-PS): Combining the *P*-value from paired sample *t*-test on the complete *n*~1~ matched pairs and the *P*-value from linear regression model using propensity score as covariate on the incomplete *n*~2~ and *n*~3~ samples.

Single biomarker
----------------

We first evaluate the performance of propensity score methods in adjusting for unbalanced covariates in single biomarker setting. [Table 1](#t1-cin-suppl.7-2014-001){ref-type="table"} reports the average empirical Type I error at nominal *α* = 0.05 over 10,000 replications. When there is no confounding effect, ie, *β* = 0, all the methods control the Type I error. However, for *β* ≠ 0, the two-sample method exhibits the largest Type I error inflation. On the other hand, paired only, FM-PS, and Reg-PS methods control the Type I error under all the scenarios considered in the simulation. [Figure 1](#f1-cin-suppl.7-2014-001){ref-type="fig"} shows the average power for different combinations of *n*~1~, *n*~2~, *n*~3~, and *β* for methods that control the Type I error (empirical Type I error ≤ 0.055). As expected, missing samples in incomplete matched pairs reduce the power compared to complete data set (Gold-std). However, incorporating the incomplete matched pairs with proper adjustment for confounders via FM-PS or Reg-PS methods exhibit increased statistical power compared to using only the *n*~1~ paired samples when *n*~2~ and *n*~3~ are substantially large. When *n*~2~ and *n*~3~ are small relative to *n*~1~, using only the *n*~1~ paired samples is comparable to methods that incorporate *n*~2~ and *n*~3~. Both FM-PS and Reg-PS methods show comparable performance in this simulation study.

Multiple biomarkers
-------------------

As omics data involve testing multiple biomarkers simultaneously (within a multiple hypothesis testing framework), we also simulate the observations from multiple biomarkers setting. We consider 1000 biomarkers and repeat each simulation setting over 100 replications. We use the false discovery rate (FDR) procedure of Benjamini and Hochberg[@b24-cin-suppl.7-2014-001] to adjust for multiple hypothesis testing. [Figure 2](#f2-cin-suppl.7-2014-001){ref-type="fig"} reports the average empirical FDR for the different methods at nominal FDR = 0.05. Similar to the single biomarker case, two-sample method exhibits the largest inflated empirical FDR for *β* ≠ 0. On the other hand, FM-PS, Reg-PS, and paired only methods control the FDR across the different scenarios. [Figure 3](#f3-cin-suppl.7-2014-001){ref-type="fig"} shows the empirical false nondiscovery rate (FNR) for the methods under comparison. FNR is an analog of Type II error in multiple hypothesis testing settings, and is defined as the proportion of false negatives among the total number of non-rejection. Empirical FNR is large when the number of incomplete matched pairs is large. On the other hand, both FM-PS and Reg-PS methods result in lower FNR compared to paired only method.

Case Study
==========

We illustrate the proposed propensity score adjustment for partially matched samples on a publicly available DNA methylation data from Selamat et al.[@b25-cin-suppl.7-2014-001] (downloaded from Gene Expression Omnibus (GEO) under accession number GSE32861). The data set consists of 58 matched pairs of lung adenocarcinoma and adjacent non-tumor lung tissue after removing paired sample 3023_T/N.[@b25-cin-suppl.7-2014-001] Methylation for these samples was profiled using the Illumina HumanMethylation27 BeadChip, which covers 27,578 CpGs. We use a subset of baseline covariates measured for each sample (ie, age, smoking status, stage, recurrence, KRAS mutation, EGFR mutation, and LKB1 mutation) to illustrate the performance of the different methods. Age and stage are continuous and ordinal variables, respectively, whereas the other covariates are binary variables.

We randomly choose *n*~1~ out of 58 matched pairs to be complete matched pairs. Next, we generate 58 − *n*~1~ indicator variables, ie, *δ~k~*, *k* = 1, ..., 58 − *n*~1~, where $$P(\delta_{k} = 1) = \frac{\exp(\beta^{t}Z_{k})}{1 + \exp(\beta^{t}Z_{k})}$$

and $$\beta^{t}Z_{k} = \text{Age}_{k} - \text{Smoke}_{k} + \text{Stage}_{k} - \text{Recur}_{k} + KRAS_{k} - \text{EGFR}_{k} + \text{LKB1}_{k}$$

after standardizing each covariate. This function generates approximately equal number of 0s and 1s on average. Among the remaining 58 -- *n*~1~ pairs, we set *n*~2~ pairs to be missing in non-tumor lung tissue corresponding to those with *δ~k~* = 1, and the remaining to be missing in lung adenocarcinoma. We consider *n*~1~ = 10, 20, 30, 40, and for each *n*~1~, the process is repeated 50 times.

We apply FM-PS, Reg-PS, two-sample, and paired only methods on the logit-transformed methylation *β*-values, ie, log(*β*/(1 − *β*))[@b26-cin-suppl.7-2014-001],[@b27-cin-suppl.7-2014-001] of each CpG. Since CpGs that are truly differentially methylated between lung adenocarcinoma and non-tumor lung tissues are unknown in the case study, we use the results from paired sample *t*-test on the full 58 matched pairs as Gold-std. We define the true positive CpGs as the subset of CpGs that are significant at the Benjamini and Hochberg[@b24-cin-suppl.7-2014-001] FDR of 0.05 for the Gold-std method. We compare the list of significant CpGs identified by FM-PS, Reg-PS, two-sample, and paired only methods at FDR = 0.05 to the true positive CpGs. In [Table 2](#t2-cin-suppl.7-2014-001){ref-type="table"}, we report the average empirical FDR, FNR, and average true positive (ATP) CpGs identified by each method. The ATP CpG is also the number of overlapping CpGs identified by each method and the Gold-std method. Two-sample method declares a larger number of false positives as indicated by the inflated empirical FDR. In this case study, the effect of confounding is moderate; thus, FM-PS, Reg-PS, and paired only methods are able to control the FDR. However, both FM-PS and Reg-PS methods have lower FNR and larger ATP compared to paired only method. This shows that the propensity score method for partially matched samples is able to adjust for confounders and improve the power of detecting differentially methylated CpGs.

We carry out a gene ontology (GO) analysis to provide biological insights into the list of significant CpGs at FDR = 0.05 identified from the Gold-std method using the Bioconductor package topGO.[@b28-cin-suppl.7-2014-001] We consider both the *elim* Fisher's exact test (elim.Fisher) and *elim* Kolmogorov--Smirnov test (elim.KS) implemented in topGO based on Alexa et al.[@b29-cin-suppl.7-2014-001] The *elim* method has been shown to improve interpretation of the GO analysis by integrating GO graph topology and iteratively removing genes that map to significant GO terms from a higher level GO terms.[@b29-cin-suppl.7-2014-001] The *P*-values from each of the test are adjusted via the Benjamini--Hochberg method.[@b24-cin-suppl.7-2014-001] [Tables 3](#t3-cin-suppl.7-2014-001){ref-type="table"}--[5](#t5-cin-suppl.7-2014-001){ref-type="table"} report the GO terms corresponding to biological process (BP), molecular function (MF), and cellular component (CC) that exhibit adjusted *P*-values \<0.05 by both the elim.Fisher and elim.KS test, respectively. For example, the BP GO analysis identifies a GO term related to positive regulation of ERK1 and ERK2 cascade, which has been shown to be implicated in lung adenocarcinomas.[@b30-cin-suppl.7-2014-001],[@b31-cin-suppl.7-2014-001]

Discussion
==========

Partially matched samples could give rise to unbalanced covariate distribution among the incomplete matched pairs in large-scale matched pair omics studies. This paper extends the *P*-value pooling method of Kuan and Huang[@b5-cin-suppl.7-2014-001] to a framework based on propensity score for adjusting unbalanced covariate distribution among the incomplete matched pairs. We consider two approaches using propensity score, namely, (1) full matching followed by generalized *t*-test (FM-PS) and (2) propensity score as covariate in regression model (Reg-PS). Both methods are able to reduce the number of false positives by accounting for the confounders. Currently, we use the full matching approach based on Mahalanobis distance with propensity score calipers[@b15-cin-suppl.7-2014-001]--[@b17-cin-suppl.7-2014-001] and the one-way random effects ANOVA model[@b19-cin-suppl.7-2014-001] for deriving the generalized paired *t*-test. One can also use other matching algorithms based on propensity score.[@b10-cin-suppl.7-2014-001]

In this paper, we assume that the biomarker measurements are properly transformed such that they are approximately Gaussian distributed. If Gaussian assumption is violated, one can replace the generalized paired *t*-test with the generalized non-parametric aligned rank test of Hodges and Lehmann[@b20-cin-suppl.7-2014-001] and Heller et al.[@b21-cin-suppl.7-2014-001] in FM-PS method, and replace regular linear regression with generalized linear models.[@b11-cin-suppl.7-2014-001] For instance, in our case study on DNA methylation, the analysis is carried out on the logit transformed beta values (also known as *M* values). An alternative approach is to analyze the untransformed beta values using beta regression in the Reg-PS method. The choice of analyzing DNA methylation data on either beta values or *M* values is an ongoing active research.[@b32-cin-suppl.7-2014-001],[@b33-cin-suppl.7-2014-001]

Both the FM-PS and Reg-PS methods exhibit comparable performance in both our simulations and case study. In this paper, we assume a linear propensity score--outcome relationship that enables us to apply direct adjustment with a linear propensity score term in Reg-PS. In such cases, Reg-PS method is computationally more efficient and easier to implement compared to FM-PS method. However, if the propensity score--outcome relationship is non-linear, one will need to consider more complicated models, for instance, the generalized additive model (GAM) as proposed in Myers and Louis.[@b34-cin-suppl.7-2014-001] In such cases, the FM-PS method may be a better alternative as this approach does not require specification of the propensity score--outcome relationship. Thus, we recommend that the users compare the results from both Reg-PS and FM-PS methods in practice.
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**Notes**: ○: Gold-std, ∆: FM-PS, +: Reg-PS, ×: two-sample, and ⋄: paired only.](cin-suppl.7-2014-001f3){#f3-cin-suppl.7-2014-001}

###### 

Average empirical Type I error at nominal *α* = 0.05. Italicized values indicate that the empirical Type I error is greater than 0.055.

  METHOD                                  *β*= 0   *β*= 0.5   *β*= 1     *β*= 2
  --------------------------------------- -------- ---------- ---------- ----------
  *n*~1~ = 70, *n*~2~ = 15, *n*~3~ = 15                                  
  Gold-std                                0.0455   0.0473     0.0503     0.0501
  Paired only                             0.0479   0.0494     0.0490     0.0518
  Two-sample                              0.0475   *0.0643*   *0.0794*   *0.0922*
  FM-PS                                   0.0462   0.0485     0.0469     0.0476
  Reg-PS                                  0.0480   0.0502     0.0441     0.0442
  *n*~1~ = 50, *n*~2~ = 25, *n*~3~ = 25                                  
  Gold-std                                0.0527   0.0541     0.0495     0.0541
  Paired only                             0.0486   0.0536     0.0534     0.0531
  Two-sample                              0.0476   *0.1044*   *0.1460*   *0.1809*
  FM-PS                                   0.0483   0.0467     0.0465     0.0485
  Reg-PS                                  0.0494   0.0476     0.0443     0.0416
  *n*~1~ = 30, *n*~2~ = 35, *n*~3~ = 35                                  
  Gold-std                                0.0522   0.0543     0.0483     0.0489
  Paired only                             0.0507   0.0494     0.0499     0.0465
  Two-sample                              0.0522   *0.1712*   *0.2805*   *0.3663*
  FM-PS                                   0.0449   0.0454     0.0422     0.0460
  Reg-PS                                  0.0524   0.0479     0.0452     0.0446

###### 

Average empirical FDR, FNR, and ATP at nominal FDR = 0.05.

  METHOD                                  PAIRED ONLY   TWO-SAMPLE   FM-PS    Reg-PS
  --------------------------------------- ------------- ------------ -------- --------
  *n*~1~ = 10, *n*~2~ = 24, *n*~3~ = 24                                       
  FDR                                     0.0304        0.0822       0.0285   0.0256
  FNR                                     0.5439        0.2121       0.4649   0.4478
  ATP                                     3457          13722        6908     7527
  *n*~1~ = 20, *n*~2~ = 19, *n*~3~ = 19                                       
  FDR                                     0.0322        0.0625       0.0256   0.0247
  FNR                                     0.4443        0.1897       0.4053   0.3810
  ATP                                     7690          14014        8941     9568
  *n*~1~ = 30, *n*~2~ = 14, *n*~3~ = 14                                       
  FDR                                     0.0352        0.0537       0.0393   0.0333
  FNR                                     0.3512        0.1632       0.3241   0.2948
  ATP                                     10422         14395        11183    11715
  *n*~1~ = 40, *n*~2~ = 9, *n*~3~ = 9                                         
  FDR                                     0.0354        0.0648       0.0404   0.0534
  FNR                                     0.2404        0.1193       0.2269   0.1803
  ATP                                     12955         15028        13201    13973

###### 

Significant BP GO terms for the CpGs identified by the Gold-std method in the lung adenocarcinoma case study. The reported *P*-values are adjusted via the Benjamini--Hochberg FDR control.[@b24-cin-suppl.7-2014-001]

  BIOLOGICAL PROCESS                                                                                   
  -------------------- ------------------------------------------- ------- ------ --------- ---------- ----------
  GO:0007268           Synaptic transmission                       1153    803    685.54    2.18e-07   2.54e-17
  GO:0048704           Embryonic skeletal system morphogenesis     159     120    94.54     0.0122     1.94e-ll
  GO:0031424           Keratinization                              58      53     34.49     0.00019    2.97e-ll
  GO:0007155           Cell adhesion                               1577    1067   937.64    0.0122     7.27e-08
  GO:0048265           Response to pain                            54      46     32.11     0.0139     9.22e-08
  GO:0009952           Anterior/posterior pattern specification    350     246    208.1     0.0283     1.21e-07
  GO:0007156           Homophilic cell adhesion                    177     133    105.24    0.0102     1.29e-07
  GO:0007186           G-protein coupled receptor signaling pat.   1035    721    615.38    0.000349   6.24e-06
  GO:0007193           Adenylate cyclase-inhibiting G-protein c.   91      73     54.11     0.0122     6.24e-06
  GO:0007267           Cell-cell signaling                         1923    1319   1143.36   0.0122     6.24e-06
  GO:0070374           Positive regulation of ERK1 and ERK2 cas.   0.174   128    103.46    0.0201     3.26e-05
  GO:0050911           Detection of chemical stimulus involved.    19      19     11.3      0.0161     4.15e-05
  GO:0001755           Neural crest cell migration                 80      65     47.57     0.0122     4.15e-05
  GO:0023019           Signal transduction involved in regulati.   33      30     19.62     0.0201     4.15e-05
  GO:0007204           Elevation of cytosolic calcium ion conce.   326     240    193.83    0.0322     9.08e-05
  GO:0048484           Enteric nervous system development          30      28     17.84     0.0139     9.73e-05
  GO:0030198           Eextracellular matrix organization          537     375    319.28    0.0102     9.73e-05
  GO:0021527           Spinal cord association neuron different.   27      25     16.05     0.0322     0.000155
  GO:0042742           Defense response to bacterium               209     150    124.27    0.0313     0.000266
  GO:0006954           Inflammatory response                       845     564    502.41    0.0217     0.000556
  GO:0030855           Epithelial cell differentiation             905     611    538.09    0.0139     0.00112
  GO:0045666           Positive regulation of neuron differenti.   112     86     66.59     0.0217     0.00185
  GO:0030335           Positive regulation of cell migration       428     294    254.48    0.0139     0.00265
  GO:0019233           Sensory perception of pain                  137     105    81.46     0.0122     0.00301
  GO:0048485           Sympathetic nervous system development      45      40     26.76     0.0122     0.00496
  GO:0045165           Cell fate commitment                        417     299    247.94    0.034      0.00999
  GO:0007215           Glutamate receptor signaling pathway        88      75     52.32     0.0122     0.0181
  GO:0021846           Cell proliferation in forebrain             43      38     25.57     0.0139     0.0194
  GO:0007631           Feeding behavior                            155     117    92.16     0.0122     0.0273

###### 

Significant MF GO terms for the CpGs identified by the Gold-std method in the lung adenocarcinoma case study. The reported *P*-values are adjusted via the Benjamini--Hochberg FDR control.[@b24-cin-suppl.7-2014-001]

  MOLECULAR FUNCTION                                                                                
  -------------------- ------------------------------------------- ------ ----- -------- ---------- ----------
  GO:0004930           G-protein coupled receptor activity         741    566   440.86   2.51e-10   1.67e-22
  GO:0004984           Olfactory receptor activity                 67     62    39.86    7.72e-07   2.26e-15
  GO:0005509           Calcium ion binding                         977    654   581.27   0.000243   1.29e-13
  GO:0043565           Sequence-specific DNA binding               1129   735   671.71   0.00888    5.34e-12
  GO:0005201           Extracellular matrix structural constitu.   123    95    73.18    0.00634    1.81e-08
  GO:0005234           Extracellular-glutamate-gated ion channe.   29     26    17.25    0.0283     6.5e-07
  GO:0005125           Cytokine activity                           332    234   197.53   0.00604    1.33e-05
  GO:0005230           Extracellular ligand-gated ion channel a.   122    99    72.58    0.0147     3.79e-05
  GO:0004890           GABA-A receptor activity                    33     29    19.63    0.0283     6e-05
  GO:0015269           Calcium-activated potassium channel acti.   27     25    16.06    0.0192     0.000132
  GO:0004888           Transmembrane signaling receptor activit.   1333   979   793.08   0.0363     0.000591
  GO:0005540           Hyaluronic acid binding                     32     29    19.04    0.0179     0.00185
  GO:0015293           Symporter activity                          213    152   126.73   0.0216     0.00232
  GO:0020037           Heme binding                                201    144   119.59   0.0216     0.00558
  GO:0005506           Iron ion binding                            238    169   141.6    0.0192     0.00558
  GO:0016918           Retinal binding                             28     25    16.66    0.0363     0.0104
  GO:0005242           Inward rectifier potassium channel activ.   37     32    22.01    0.0283     0.0126
  GO:0015279           Store-operated calcium channel activity     16     16    9.52     0.0229     0.0212
  GO:0008227           G-protein coupled amine receptor activit.   67     58    39.86    0.0216     0.0315

###### 

Significant CC GO terms for the CpGs identified by the Gold-std method in the lung adenocarcinoma case study. The reported *P*-values are adjusted via the Benjamini--Hochberg FDR control.[@b24-cin-suppl.7-2014-001]

  CELLULAR COMPONENT                                                                                  
  -------------------- ----------------------------------------- -------- ------ --------- ---------- ----------
  GO:0005887           Integral to plasma membrane               2079     1443   1242.77   3.14e-14   3.64e-35
  GO:0005576           Extracellular region                      3134     2161   1873.41   1.35e-09   1.82e-27
  GO:0005615           Extracellular space                       1398     964    835.68    5.49e-ll   4.19e-25
  GO:0005886           Plasma membrane                           6289     4079   3759.38   2.08e-05   2.84e-14
  GO:0005578           Proteinaceous extracellular matrix        547      402    326.98    1.32e-07   1.39e-13
  GO:0016021           Integral to membrane                      6898     4421   4123.42   0.000363   1.86e-ll
  GO:0 04 5211         Postsynaptic membrane                     294      209    175.74    0.00296    4.46e-10
  GO:0008076           Voltage-gated potassium channel complex   117      92     69.94     0.0012     7.64e-10
  GO:0030054           Cell junction                             11 9 7   776    715.53    0.0105     2.57e-06
  GO:0034774           Secretory granule lumen                   105      79     62.77     0.0 419    0.00149
